Cost–effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer
Abstract
Aim: To evaluate the cost–effectiveness of atezolizumab plus nab-paclitaxel (ANP) in the first-line treatment of metastatic triple-negative breast cancer (TNBC). Materials & methods: We developed a Markov model to evaluate the cost and effectiveness of ANP versus nab-paclitaxel in the first-line treatment of metastatic TNBC. Lifetime costs, life-years (LYs) and quality-adjusted LYs (QALYs) were estimated. Results: ANP provided an additional 0.16 QALYs (0.24 LYs) compared with nab-paclitaxel in intention-to-treat population. The corresponding incremental cost–effectiveness ratio was $786,131 per QALY gained. However, the incremental cost–effectiveness ratio decreased to $361,218 per QALY gained in the PD-L1 positive subgroup analysis. Conclusion: From the perspective of a US-payer, ANP is estimated not to be cost-effective in the first-line treatment of metastatic TNBC.
References
- 1. . Cancer statistics, 2016. CA Cancer J. Clin. 66(1), 7–30 (2016).
- 2. . Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol. Therapeut. 199, 30–57 (2019).
- 3. . Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 9(2), 176–198 (2019).
- 4. . Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 17(1), 1–9 (2019).
- 5. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New Engl. J. Med. 379(22), 2108–2121 (2018).
- 6. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. www.nccn.org/patients
- 7. Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 34(9), 902–909 (2016).
- 8. . Improved curve fits to summary survival data: application to economic evaluation of health technologies. Bmc Med. Res. Methodol. 11, 139 (2011).
- 9. . Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives. Cancer 123(14), 2634–2641 (2017).
- 10. . United States Life Tables, 2014. National Vital Statistics Reports 66(NO.4), (2017). www.cdc.gov/nchs/products/nvsr.htm
- 11. Centers for Medicare and Medicaid Services: Medicare Part B Drug Average Sale Price. www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles
- 12. Flatiron Health. https://flatiron.com/
- 13. Centers for Medicare and Medicaid Services: Medicare Physician Fee Schedule 2014. www.cms.gov/apps/physician-fee-schedule/
- 14. The Consumer Price Index (US Bureau of Labor Statistics). www.bls.gov/data/inflation_calculator.htm
- 15. . Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). Breast 48(Suppl. 1), S44–S48 (2019).
- 16. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16(2), 231–250 (2013).
- 17. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med. Decis. Making 32(5), 722–732 (2012).
- 18. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer 130, 1–4 (2019).
- 19. . First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: a United States–based cost-effectiveness analysis. Cancer 125(20), 3526–3534 (2019).
- 20. Cost-effectiveness of digital mammography breast cancer screening. Ann. Intern. Med. 148(1), 1–10 (2008).
- 21. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. J. Comp. Eff. Res.
doi:10.2217/cer-2019-0077 (2019) (Epub ahead of print). - 22. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol. 15(17), 1951–1961 (2019).
- 23. . Health state utilities for metastatic breast cancer. Br. J. Cancer 95 683–690 (2006).
- 24. . Cost–effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. Curr. Oncol. 21, e41 (2013).